WO2012138043A3 - Therapeutic composition containing endothelin as an active component - Google Patents

Therapeutic composition containing endothelin as an active component Download PDF

Info

Publication number
WO2012138043A3
WO2012138043A3 PCT/KR2011/010320 KR2011010320W WO2012138043A3 WO 2012138043 A3 WO2012138043 A3 WO 2012138043A3 KR 2011010320 W KR2011010320 W KR 2011010320W WO 2012138043 A3 WO2012138043 A3 WO 2012138043A3
Authority
WO
WIPO (PCT)
Prior art keywords
endothelin
preventing
composition
disease
ischemia
Prior art date
Application number
PCT/KR2011/010320
Other languages
French (fr)
Other versions
WO2012138043A2 (en
Inventor
Eun Ju Lee
Hyo Soo Kim
Original Assignee
Seoul National University Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seoul National University Hospital filed Critical Seoul National University Hospital
Publication of WO2012138043A2 publication Critical patent/WO2012138043A2/en
Publication of WO2012138043A3 publication Critical patent/WO2012138043A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention relates to a composition for preventing or treating ischemic disease comprising endothelin or a nucleotide sequence encoding endothelin as an active ingredient, and more particularly to a composition for preventing or treating ischemic heart disease, myocardial infarction, angina pectoris, lower limb artery ischemia, distal limb ischemia and ischemic cerebrovascular disease, wherein the composition is administered by intramuscular injection. According to the present invention, administering endothelin-1 by intramuscular injection may efficiently inhibit the progress of ischemia, fibrosis and tissue necrosis, and induce angiogenesis, such that it is promising for preventing or treating the ischemic disease.
PCT/KR2011/010320 2011-04-04 2011-12-29 Therapeutic composition containing endothelin as an active component WO2012138043A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0030465 2011-04-04
KR1020110030465A KR101418941B1 (en) 2011-04-04 2011-04-04 Therapeutic Composion Containing Endothelin as an Active Component

Publications (2)

Publication Number Publication Date
WO2012138043A2 WO2012138043A2 (en) 2012-10-11
WO2012138043A3 true WO2012138043A3 (en) 2012-11-29

Family

ID=46969630

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/010320 WO2012138043A2 (en) 2011-04-04 2011-12-29 Therapeutic composition containing endothelin as an active component

Country Status (2)

Country Link
KR (1) KR101418941B1 (en)
WO (1) WO2012138043A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2817638C2 (en) * 2022-08-03 2024-04-17 Юрий Валентинович Червяков Method of treating chronic lower limb ischemia of ii and iii degree of atherosclerotic genesis in occluding lesions of aorto-femoral segment

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102458399B (en) 2009-04-30 2014-04-23 美国中西部大学 Novel therapeutic treatments using centhaquin
PL3019242T3 (en) * 2013-07-08 2021-02-08 Midwestern University Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104976A1 (en) * 2001-07-23 2003-06-05 Gudarz Davar Analgesic methods using endothelin receptor ligands
WO2007112069A2 (en) * 2006-03-23 2007-10-04 Amylin Pharmaceuticals, Inc. Endothelin and endothelin receptor agonists in the treatment of metabolic diseases
US20100209433A1 (en) * 2005-12-01 2010-08-19 B.R.A.H.M.S Aktiengesellschaft Methods for the diagnosis and for the treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104976A1 (en) * 2001-07-23 2003-06-05 Gudarz Davar Analgesic methods using endothelin receptor ligands
US20100209433A1 (en) * 2005-12-01 2010-08-19 B.R.A.H.M.S Aktiengesellschaft Methods for the diagnosis and for the treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
WO2007112069A2 (en) * 2006-03-23 2007-10-04 Amylin Pharmaceuticals, Inc. Endothelin and endothelin receptor agonists in the treatment of metabolic diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HO, M. C. Y. ET AL.: "Endothelin-1 protects astrocytes from hypoxic/ischemic injury.", THE FASEB JOURNAL., vol. 15, 2001, pages 618 - 626 *
MIMA, T. ET AL.: "Endothelin acts in feline and canine cerebral arteries from the adventitial side.", STROKE., vol. 20, 1989, pages 1553 - 1556 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2817638C2 (en) * 2022-08-03 2024-04-17 Юрий Валентинович Червяков Method of treating chronic lower limb ischemia of ii and iii degree of atherosclerotic genesis in occluding lesions of aorto-femoral segment

Also Published As

Publication number Publication date
WO2012138043A2 (en) 2012-10-11
KR101418941B1 (en) 2014-07-15
KR20120112894A (en) 2012-10-12

Similar Documents

Publication Publication Date Title
CL2014000504A1 (en) Compounds derived from substituted condensed pyrimidines; preparation procedure; pharmaceutical composition; and use in the treatment and / or prevention of heart failure, angina pectoris, hypertension, among other diseases.
EA201391000A1 (en) INDOL CONNECTIONS OR THEIR ANALOGUES USEFUL FOR THE TREATMENT OF AGE MAKULAR DEGENERATION (AMD)
EA201291233A1 (en) ANALOGUE GLUACAGONA
EA201291234A1 (en) ANALOGUE GLUACAGONA
CA2797033C (en) Highly active polypeptides and methods of making and using the same
EA201391315A1 (en) GUANIDINE CONNECTION
MY165754A (en) Catalyst for producing acrylic acids and acrylates
CU20160013A7 (en) CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE
EA201390428A1 (en) COMPOSITIONS AND METHODS OF TREATMENT OF PULMONARY HYPERTENSION
TN2014000318A1 (en) Synthetic apelin mimetics for the treatment of heart failure
MX2012015097A (en) Napht- 2 -ylacetic acid derivatives to treat aids.
MX2012000564A (en) Acylated glucagon analogues.
WO2013092703A3 (en) Glucagon analogues
UA105556C2 (en) Combination of compounds comprising hiv integrase inhibitors with other therapeutical agents
WO2012104263A3 (en) 1,4 oxazines as bace1 and/or bace2 inhibitors
WO2011097335A3 (en) Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
WO2012006516A3 (en) Protein kinase c activators and anticoagulant for the treatment of stroke
MX2012003324A (en) Glycine compound.
WO2012113873A3 (en) Organic compounds
TW201613932A (en) Organic compounds
WO2010028173A3 (en) Method of treating atrial fibrillation
AU2014362144A2 (en) 5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative
WO2014016754A3 (en) Pharmaceutical compositions of proton pump inhibitor
WO2012138043A3 (en) Therapeutic composition containing endothelin as an active component
CO2020006789A2 (en) Procedure for the preparation of (3s) -3- (4-chloro-3 - {[(2s, 3r) -2- (4-chlorophenyl) -4,4,4-trifluoro-3-methylbutanoyl] amino} phenyl) -3-cyclopropylpropanoic acid and its crystalline form for use as an active pharmaceutical ingredient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11862870

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11862870

Country of ref document: EP

Kind code of ref document: A2